Zhaoshi Bao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9537634/publications.pdf

Version: 2024-02-01

32 papers	2,138 citations	471371 17 h-index	414303 32 g-index
33 all docs	33 docs citations	33 times ranked	2380 citing authors

#	Article	IF	Citations
1	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	3.2	448
2	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics, Proteomics and Bioinformatics, 2021, 19, 1-12.	3.0	439
3	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell, 2018, 175, 1665-1678.e18.	13.5	250
4	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	3.2	194
5	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology, 2012, 14, 1432-1440.	0.6	163
6	MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nature Communications, 2020, 11, 3883.	5.8	110
7	MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget, 2014, 5, 12908-12915.	0.8	54
8	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget, 2015, 6, 7318-7324.	0.8	40
9	Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. Frontiers of Medicine, 2021, 15, 551-561.	1.5	39
10	Interplay between PCBP2 and miRNA modulates ARHGDIA expression and function in glioma migration and invasion. Oncotarget, 2016, 7, 19483-19498.	0.8	39
11	KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4. Oncotarget, 2016, 7, 24646-24655.	0.8	33
12	BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. Journal of Translational Medicine, 2013, 11, 100.	1.8	32
13	PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas. Cellular and Molecular Life Sciences, 2015, 72, 4383-4397.	2.4	32
14	ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion. PLoS ONE, 2015, 10, e0142856.	1.1	28
15	Identification of miRNA-Mediated Core Gene Module for Glioma Patient Prediction by Integrating High-Throughput miRNA, mRNA Expression and Pathway Structure. PLoS ONE, 2014, 9, e96908.	1.1	26
16	CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression. Journal of Neuro-Oncology, 2017, 133, 87-95.	1.4	24
17	SOCS3 Promoter Hypermethylation Is a Favorable Prognosticator and a Novel Indicator for G-CIMP-Positive GBM Patients. PLoS ONE, 2014, 9, e91829.	1.1	21
18	Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. Journal of Neurosurgery, 2017, 126, 249-259.	0.9	19

#	Article	IF	Citations
19	Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget, 2014, 5, 7342-7356.	0.8	19
20	Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. Oncology Reports, 2015, 34, 1503-1509.	1.2	16
21	SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. Frontiers in Immunology, 2021, 12, 659659.	2.2	16
22	Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma. Cell Death and Disease, 2021, 12, 1140.	2.7	16
23	PABPC1 relevant bioinformatic profiling and prognostic value in gliomas. Future Oncology, 2020, 16, 4279-4288.	1.1	14
24	Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma. Oncology Reports, 2014, 32, 250-260.	1.2	12
25	LINC00174 is a favorable prognostic biomarker in glioblastoma via promoting proliferative phenotype. Cancer Biomarkers, 2020, 28, 1-7.	0.8	10
26	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. Disease Markers, 2018, 2018, 1-8.	0.6	9
27	Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. Aging, 2018, 10, 1977-1988.	1.4	8
28	Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma. Aging, 2022, 14, 2320-2334.	1.4	7
29	Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study. Radiotherapy and Oncology, 2022, 167, 1-6.	0.3	3
30	NCMP-28. PTPRZ1-MET SIGNALING PROMOTES GLIOMA PROGRESSION THROUGH STIMULATION THE TRANSFORMATION FROM M1 TO M2 MACROPHAGE. Neuro-Oncology, 2018, 20, vi199-vi199.	0.6	1
31	Comprehensive analysis of the LncRNAs, MiRNAs, and MRNAs acting within the competing endogenous RNA network of LGG. Genetica, 2022, 150, 41.	0.5	1
32	LRRFIP1, an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma. CNS Neuroscience and Therapeutics, 2022, 28, 873-883.	1.9	1